Lili Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lili Ding has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China
19 shared publications Zhengtao Wang
14 shared publicationsXunjiang Wang
12 shared publications- Zhengtao Wang
Shanghai University of Traditional Chinese Medicine
12 shared publications Li Yang
7 shared publicationsTongxi Zhuang
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Key Laboratory of Compound Chinese Medicines and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
7 shared publications
Latest Publications
- 18 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161
Schisandrin A ameliorates obesity and MAFLD through bile acid context-dependent modulation of intestinal FXR signaling
- 18 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161
Schisandrin A ameliorates obesity and MAFLD through bile acid context-dependent modulation of intestinal FXR signaling
- Open Access
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
Gut microbiota-bile acid-intestinal FXR signaling mediates the anti-sarcopenic effects of Jianpi Qiangji Granule
Background: Sarcopenia is characterized by declining muscle mass and function, with no approved pharmacological therapy currently available. Jianpi Qiangji Granule (JQG) has demonstrated clinical benefits in patients with sarcopenia; however, the underlying mechanisms remain unclear. This study investigated whether JQG alleviates sarcopenia through regulation of the gut microbiota-bile acid (BA)-FXR signaling.Methods: The therapeutic effects of JQG were evaluated using samples from a randomized positive-controlled clinical trial and a dexamethasone (Dex)-induced sarcopenic mouse model. Gut microbiota and BA profiles were characterized by 16S rRNA sequencing and metabolomic analyses. Antibiotic-mediated microbiota depletion, fecal microbiota transplantation, and intestinal epithelial cell-specific Fxr knockout mice were used to determine microbiota and FXR dependence. Recombinant fibroblast growth factor 15 (FGF15) treatment and fibroblast growth factor receptor 4 (FGFR4) silencing in C2C12 myoblasts and primary muscle satellite cells were performed to define downstream mechanisms. Results: JQG improved muscle strength and physical performance in patients and alleviated Dex-induced muscle atrophy and functional decline in mice. Mechanistically, JQG enriched bile salt hydrolase- producing bacteria, enhanced BA deconjugation, increased free BAs, and activated intestinal FXR-FGF15 signaling. Microbiota depletion abolished JQG-induced BA remodeling, FXR activation, and muscle protection, whereas fecal microbiota transplantation transferred these benefits to recipient mice. Intestinal Fxr deletion largely abrogated the therapeutic effects of JQG. of JQG. Furthermore, FGF15 directly protected myotubes against Dex-induced atrophy, whereas FGFR4 knockdown abolished FGF15-mediated myogenic responses.Conclusions: JQG ameliorates sarcopenia by remodeling the gut microbiota and BA pool, thereby activating an intestinal FXR-FGF15-muscle FGFR4 endocrine pathway that promotes skeletal muscle regeneration.
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGut microbiota-bile acid-intestinal FXR signaling mediates the anti-sarcopenic effects of Jianpi Qiangji Granule
Background: Sarcopenia is characterized by declining muscle mass and function, with no approved pharmacological therapy currently available. Jianpi Qiangji Granule (JQG) has demonstrated clinical benefits in patients with sarcopenia; however, the underlying mechanisms remain unclear. This study investigated whether JQG alleviates sarcopenia through regulation of the gut microbiota-bile acid (BA)-FXR signaling.Methods: The therapeutic effects of JQG were evaluated using samples from a randomized positive-controlled clinical trial and a dexamethasone (Dex)-induced sarcopenic mouse model. Gut microbiota and BA profiles were characterized by 16S rRNA sequencing and metabolomic analyses. Antibiotic-mediated microbiota depletion, fecal microbiota transplantation, and intestinal epithelial cell-specific Fxr knockout mice were used to determine microbiota and FXR dependence. Recombinant fibroblast growth factor 15 (FGF15) treatment and fibroblast growth factor receptor 4 (FGFR4) silencing in C2C12 myoblasts and primary muscle satellite cells were performed to define downstream mechanisms. Results: JQG improved muscle strength and physical performance in patients and alleviated Dex-induced muscle atrophy and functional decline in mice. Mechanistically, JQG enriched bile salt hydrolase- producing bacteria, enhanced BA deconjugation, increased free BAs, and activated intestinal FXR-FGF15 signaling. Microbiota depletion abolished JQG-induced BA remodeling, FXR activation, and muscle protection, whereas fecal microbiota transplantation transferred these benefits to recipient mice. Intestinal Fxr deletion largely abrogated the therapeutic effects of JQG. of JQG. Furthermore, FGF15 directly protected myotubes against Dex-induced atrophy, whereas FGFR4 knockdown abolished FGF15-mediated myogenic responses.Conclusions: JQG ameliorates sarcopenia by remodeling the gut microbiota and BA pool, thereby activating an intestinal FXR-FGF15-muscle FGFR4 endocrine pathway that promotes skeletal muscle regeneration.
- 16 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158600
Enrichment of Akkermansia muciniphila by red ginseng promotes GDF15 secretion and suppresses obesity in mice
- 16 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158600
Enrichment of Akkermansia muciniphila by red ginseng promotes GDF15 secretion and suppresses obesity in mice
- Open Access
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Schisantherin A interacts with gut bacteria to stimulate adipose tissue thermogenesis in obese mice via a TGR5‒p-CREB‒STAT6 signaling pathway
The global epidemic of obesity challenges the scientific and medical communities to find different treatments. Schisantherin A (Sin A), a natural compound isolated from Schisandra chinensis (Turcz.), reduces the abundance of bile salt hydrolase-producing gut bacteria in obese mice, leading to accumulation of specific conjugated bile acids (CBAs). These elevated CBAs activate a signaling axis containing Takeda G protein-coupled receptor 5, phosphorylated cAMP-responsive element binding protein 1, and signal transducer and activator of transcription 6 (TGR5–p-CREB–STAT6), wherein CREB directly binds to the STAT6 promoter. Sin A-induced STAT6 activation promoted M2-like macrophages polarization to secret slit guidance ligand 3 (SLIT3), which consequently stimulated norepinephrine release in sympathetic neurons and induced thermogenesis in adipose tissue. This study thus identifies a pathway by which Sin A interacts with gut bacteria to stimulate CBA-mediated beiging of white adipose tissue, highlighting a promising natural product-based strategy for obesity treatment.
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessSchisantherin A interacts with gut bacteria to stimulate adipose tissue thermogenesis in obese mice via a TGR5‒p-CREB‒STAT6 signaling pathway
The global epidemic of obesity challenges the scientific and medical communities to find different treatments. Schisantherin A (Sin A), a natural compound isolated from Schisandra chinensis (Turcz.), reduces the abundance of bile salt hydrolase-producing gut bacteria in obese mice, leading to accumulation of specific conjugated bile acids (CBAs). These elevated CBAs activate a signaling axis containing Takeda G protein-coupled receptor 5, phosphorylated cAMP-responsive element binding protein 1, and signal transducer and activator of transcription 6 (TGR5–p-CREB–STAT6), wherein CREB directly binds to the STAT6 promoter. Sin A-induced STAT6 activation promoted M2-like macrophages polarization to secret slit guidance ligand 3 (SLIT3), which consequently stimulated norepinephrine release in sympathetic neurons and induced thermogenesis in adipose tissue. This study thus identifies a pathway by which Sin A interacts with gut bacteria to stimulate CBA-mediated beiging of white adipose tissue, highlighting a promising natural product-based strategy for obesity treatment.
- Open Access
- 20 November 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50  (3) , 100920
20(S)-protopanaxatriol ameliorates cardiac hypertrophy by activating the AMPK/PGC-1α/PPARγ signaling pathway
- 20 November 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50  (3) , 100920
Open Access20(S)-protopanaxatriol ameliorates cardiac hypertrophy by activating the AMPK/PGC-1α/PPARγ signaling pathway
- 25 August 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 323  (Pt 1) , 147082
Lithospermum erythrorhizon polysaccharide alleviates obesity via gut microbiota-mediated reprogramming of bile acid and short-chain fatty acid metabolism
- 25 August 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 323  (Pt 1) , 147082
Lithospermum erythrorhizon polysaccharide alleviates obesity via gut microbiota-mediated reprogramming of bile acid and short-chain fatty acid metabolism
- 27 May 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 265, 116989
Targeted metabolomics for multiple energy metabolites of tricarboxylic acid cycle, glycolysis and oxidative phosphorylation pathway in MAFLD: From analytical method development towards application to authentic samples in mice and human
- 27 May 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 265, 116989
Targeted metabolomics for multiple energy metabolites of tricarboxylic acid cycle, glycolysis and oxidative phosphorylation pathway in MAFLD: From analytical method development towards application to authentic samples in mice and human
- Open Access
- 12 March 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20  (1) , 1-15
Chlorogenic acid attenuates pyrrolizidine alkaloid-induced liver injury through modulation of the SIRT1/FXR signaling pathway
Background: Pyrrolizidine alkaloids (PAs), recognized globally for their hepatotoxic properties, significantly contribute to liver damage through an imbalance in bile acid homeostasis. Addressing this imbalance is crucial for therapeutic interventions in PA-related liver injuries. Chlorogenic acid (Cga), a phenolic compound derived from medicinal plants, has demonstrated hepato-protective effects across a spectrum of liver disorders. The specific influence and underlying mechanisms by which Cga mitigates PA-induced liver damage have not been clearly defined. Materials and methods: To explore the protective effects of Cga against acute PA toxicity, a murine model was established. The influence of Cga on bile acid metabolism was confirmed through a variety of molecular biology techniques. These included RNA sequencing, western blotting, and immunoprecipitation, along with quantitative analyses of bile acid concentrations. Results: Our findings indicate that Cga enhances sirtuin 1 (SIRT1) activation and increases farnesoid X receptor (FXR) signaling, which are crucial for maintaining bile acid balance in PA-induced hepatic injury. When mice subjected to PA-induced hepatic injury were treated with SIRT1 inhibitors alongside Cga, the hepatoprotective effects of Cga were significantly reduced. In Fxr-KO mice, the ability of Cga to mitigate liver damage induced by PAs was substantially reduced, which underscores the role of the SIRT1/FXR signaling axis in mediating the protective effects of Cga. Conclusion: Our research suggests that Cga can serve as an effective treatment for PA-mediated hepatotoxicity. It appears that influencing the SIRT1/FXR signaling pathway might provide an innovative pharmacological approach to address liver damage caused by PAs.
- 12 March 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20  (1) , 1-15
Open AccessChlorogenic acid attenuates pyrrolizidine alkaloid-induced liver injury through modulation of the SIRT1/FXR signaling pathway
Background: Pyrrolizidine alkaloids (PAs), recognized globally for their hepatotoxic properties, significantly contribute to liver damage through an imbalance in bile acid homeostasis. Addressing this imbalance is crucial for therapeutic interventions in PA-related liver injuries. Chlorogenic acid (Cga), a phenolic compound derived from medicinal plants, has demonstrated hepato-protective effects across a spectrum of liver disorders. The specific influence and underlying mechanisms by which Cga mitigates PA-induced liver damage have not been clearly defined. Materials and methods: To explore the protective effects of Cga against acute PA toxicity, a murine model was established. The influence of Cga on bile acid metabolism was confirmed through a variety of molecular biology techniques. These included RNA sequencing, western blotting, and immunoprecipitation, along with quantitative analyses of bile acid concentrations. Results: Our findings indicate that Cga enhances sirtuin 1 (SIRT1) activation and increases farnesoid X receptor (FXR) signaling, which are crucial for maintaining bile acid balance in PA-induced hepatic injury. When mice subjected to PA-induced hepatic injury were treated with SIRT1 inhibitors alongside Cga, the hepatoprotective effects of Cga were significantly reduced. In Fxr-KO mice, the ability of Cga to mitigate liver damage induced by PAs was substantially reduced, which underscores the role of the SIRT1/FXR signaling axis in mediating the protective effects of Cga. Conclusion: Our research suggests that Cga can serve as an effective treatment for PA-mediated hepatotoxicity. It appears that influencing the SIRT1/FXR signaling pathway might provide an innovative pharmacological approach to address liver damage caused by PAs.
- 13 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156513
Panax notoginseng saponins ameliorate LPS-induced acute lung injury by promoting STAT6-mediated M2-like macrophage polarization
- 13 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156513
Panax notoginseng saponins ameliorate LPS-induced acute lung injury by promoting STAT6-mediated M2-like macrophage polarization
- Open Access
- 8 November 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 75, 779-792
Biological functions and pharmacological behaviors of bile acids in metabolic diseases
- 8 November 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 75, 779-792
Open AccessBiological functions and pharmacological behaviors of bile acids in metabolic diseases